Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

New Lab Technology Will Boost Cell Therapy Applications

By BiotechDaily International staff writers
Posted on 25 Nov 2013
Image: The Xuri Cell Expansion System W25 (Photo courtesy of GE Healthcare).
Image: The Xuri Cell Expansion System W25 (Photo courtesy of GE Healthcare).
A newly released family of cell culture systems was designed specifically to support and advance the growing field of cell therapy.

The Xuri Cell Expansion System W25 is the first member of GE Healthcare's (Chalfont St. Giles, United Kingdom) new hi-tech cell culture systems to be released for sale.

This system comprises a reliable and intuitive device for expansion of human cell cultures for cellular therapy purposes. It employs single-use, functionally closed disposables to minimize risk of contamination. The Xuri system can accommodate working volumes from as little as one liter—appropriate for growing high-density cell cultures—with room to expand up to 25 liters. The system is based on GE Healthcare's WAVE rocking technology that provides mixing and aeration. The Xuri system is functionally closed, which minimizes the risk of cell contamination while allowing the culture to reach high cell densities.

The Xuri Cell Expansion System W25 is enhanced by sensors to monitor the cell culture environment and is operated via "UNICORN" control software. The system was designed to deliver reliable and accurate performance for research, process development, or manufacturing operations.

Eric Roman, general manager of research and applied markets at GE Healthcare, said, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, (Stockholm, Sweden) to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable, and efficient progress of cell therapies from clinical development to commercialization.”

Related Links:

GE Healthcare
Karolinska University Hospital



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.